Compare QIAGEN NV with Similar Stocks
Dashboard
1
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.91 times
2
Poor long term growth as Operating profit has grown by an annual rate 5.15% of over the last 5 years
3
Positive results in Jun 25
4
With ROCE of 13.55%, it has a very expensive valuation with a 2.70 Enterprise value to Capital Employed
5
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
USD 8,497 Million (Small Cap)
18.00
NA
0.00%
0.15
12.51%
2.25
Revenue and Profits:
Net Sales:
540 Million
(Quarterly Results - Dec 2025)
Net Profit:
108 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.71%
0%
-12.71%
6 Months
-13.12%
0%
-13.12%
1 Year
-0.9%
0%
-0.9%
2 Years
-12.88%
0%
-12.88%
3 Years
-19.31%
0%
-19.31%
4 Years
-23.77%
0%
-23.77%
5 Years
-23.42%
0%
-23.42%
QIAGEN NV for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
2.25%
EBIT Growth (5y)
-0.60%
EBIT to Interest (avg)
10.44
Debt to EBITDA (avg)
0.91
Net Debt to Equity (avg)
0.13
Sales to Capital Employed (avg)
0.39
Tax Ratio
32.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
80.89%
ROCE (avg)
13.81%
ROE (avg)
14.15%
Valuation key factors
Factor
Value
P/E Ratio
18
Industry P/E
Price to Book Value
2.25
EV to EBIT
17.35
EV to EBITDA
13.59
EV to Capital Employed
2.09
EV to Sales
4.33
PEG Ratio
11.05
Dividend Yield
NA
ROCE (Latest)
12.04%
ROE (Latest)
12.51%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot : Dec 2025
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 82 Schemes (32.84%)
Foreign Institutions
Held by 216 Foreign Institutions (28.95%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
540.40
532.60
1.46%
Operating Profit (PBDIT) excl Other Income
121.90
188.30
-35.26%
Interest
10.10
8.20
23.17%
Exceptional Items
-22.40
-9.10
-146.15%
Consolidate Net Profit
107.80
130.00
-17.08%
Operating Profit Margin (Excl OI)
225.50%
257.80%
-3.23%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 1.46% vs -0.17% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -17.08% vs 35.14% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,090.00
1,978.20
5.65%
Operating Profit (PBDIT) excl Other Income
714.10
698.20
2.28%
Interest
33.30
43.80
-23.97%
Exceptional Items
-54.50
-405.60
86.56%
Consolidate Net Profit
424.90
83.60
408.25%
Operating Profit Margin (Excl OI)
249.00%
250.20%
-0.12%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.65% vs 0.66% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 408.25% vs -75.51% in Dec 2024
About QIAGEN NV 
QIAGEN NV
Pharmaceuticals & Biotechnology
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Company Coordinates 
Company Details
Hulsterweg 82 , VENLO None : 5912 PL
Registrar Details






